antaitavir phosphate + yingqiangbuvir + midazolam

antaitavir phosphate + yingqiangbuvir + midazolam is a combination regimen primarily utilized in clinical pharmacology research by Guangdong Dongyangguang Pharmaceutical (HEC Pharm). The regimen includes two direct-acting antiviral (DAA) agents for the treatment of chronic hepatitis C: antaitavir phosphate (also known as furaprevir), an HCV NS3/4A protease inhibitor, and yingqiangbuvir (HEC110114), an HCV NS5A inhibitor. Midazolam, a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, is included in these specific clinical protocols as a probe substrate for the CYP3A4 enzyme. These studies are designed to evaluate the drug-drug interaction (DDI) potential of the antaitavir/yingqiangbuvir combination, specifically its effect on the metabolism of CYP3A4 substrates. While the DAA components are in late-stage development (Phase 3) for the treatment of hepatitis C, the inclusion of midazolam is limited to Phase 1 pharmacokinetic and safety assessments.

Other names

furaprevir phosphate + yingqiangbuvir + midazolamHEC63737 + HEC110114 + midazolamantai-tavir phosphate + yingqiangbuvir + midazolam